Co-Sponsored by:                                                         Transcatheter Heart Valve                        ...
1:30 p.m.       Surgeon’s Assessment                Michael J. Mack, MD1:45 p.m.       Essential Echocardiography: Preop A...
Friday, April 26, 2013 • 7:30 a.m. – 4:15 p.m.7:30 a.m.        Continental Breakfast8:00 a.m. – 10:15 a.m.Session 3: Case-...
2:00 p.m. – 3:45 p.m.Session 5: TAVR Outcomes and EquipoiseModerators: Susheel K. Kodali, MD and Michael J. Reardon, MD2:0...
Upcoming SlideShare
Loading in …5
×

STS/ACCF Transcatheter Heart Valve (THV) Symposium

288 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
288
On SlideShare
0
From Embeds
0
Number of Embeds
37
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

STS/ACCF Transcatheter Heart Valve (THV) Symposium

  1. 1. Co-Sponsored by: Transcatheter Heart Valve (THV) Symposium April 25-26, 2013 Omni Dallas HotelCourse DirectorsJoseph E. Bavaria, MDE. Murat Tuzcu, MDCourse Co-Directors:Samir R. Kapadia, MDSusheel K. Kodali, MDWilson Y. Szeto, MDVinod H. Thourani, MDCourse Description:STS is co-sponsoring a day-and-a-half symposium with the American College of Cardiology Foundation (ACCF) that willfocus on the latest innovations in transcatheter therapy for aortic valvular disease. Transcatheter aortic valvereplacement (TAVR) is a new, minimally invasive therapy for the management of aortic stenosis, and catheter-basedtechnology has provided a new therapeutic option for the treatment of structural heart disease.Now that TAVR has received commercial approval, STS and the ACCF are offering this symposium to preparecardiothoracic surgeons, cardiologists, and the full health care team for the still-evolving role and impact oftranscatheter heart valve (THV) therapy. Specifically, this symposium will include the latest information regardingexpanded indications for TAVR, new data from registries and clinical trials, and new financial implications of TAVR.Sessions will include hands-on device demonstrations, case presentations, and a review of the most current US andglobal experiences. Invited speakers include pioneers and leaders from specialties, including cardiothoracic surgery,interventional cardiology, echocardiography, and radiology. The distinguished faculty will also discuss the importance ofa collaborative multidisciplinary approach and provide essential information and insight for physicians and theiradministrators to support a THV program.Learning Objectives:After participating in this educational activity, participants should be able to:  Discuss the emerging technology of THV therapy;  Discuss the clinical results of transcatheter aortic valve implantation and its impact on the treatment of aortic stenosis;  Outline the importance of a collaborative multidisciplinary approach in achieving optimal outcome and managing procedural complications related to THV therapy;  Demonstrate how to use the latest catheter-based device for the treatment of valvular disease; and  Describe how to establish a collaborative THV program and develop the essential infrastructure, including the hybrid operating suite and a multidisciplinary valve clinic. Thursday, April 25, 2013 • 1:00 p.m. – 5:30 p.m.1:00 p.m. Welcome, Announcements, and Introductory Remarks Joseph E. Bavaria, MD and E. Murat Tuzcu, MD1:15 p.m. – 3:15 p.m.Session I: TAVR Patient Selection and Preparation: Case Presentation and DiscussionModerators: Joseph E. Bavaria, MD and E. Murat Tuzcu, MD1:15 p.m. Aortic Valve Anatomy and Physiology: Knowledge All TAVR Physicians Require E. Murat Tuzcu, MDAgenda and speakers are subject to change.
  2. 2. 1:30 p.m. Surgeon’s Assessment Michael J. Mack, MD1:45 p.m. Essential Echocardiography: Preop Assessment Rebecca Hahn, MD2:00 p.m. Essential Imaging: CT and MRI Jonathon A. Leipsic, MD2:15 p.m. Team Equipment and Location G. Chad Hughes, MD2:30 p.m. Radiation Exposure During TAVR: What You Don’t Know Howard Herrmann, MD2:45 p.m. Assessment of Frailty: Utility vs. Futility Thomas J. Gleason, MD3:00 p.m. Panel Discussion3:15 p.m. Break – Please Visit Exhibits3:30 p.m. – 5:30 p.m.Session 2: Case-Based Look at TAVR TechniquesModerators: Vinod H. Thourani, MD and Jeffrey Popma, MD3:30p.m. Balloon-Expandable TF TAVR Technique Gus Pichard, MD3:45 p.m. Self-Expandable TF TAVR Technique Neal Kleiman, MD4:00 p.m. Transapical TAVR Todd M. Dewey, MD4:15 p.m. Transaortic and Transaxillary TAVR Michael J. Reardon, MD4:30 p.m. Applicability of Transapical Multi-Valve and Valve-in-Valve Future Therapies Mathew Williams, MD4:45 p.m. Deciding the Approach: Putting It All Together Vinod H. Thourani, MD5:00 p.m. New TAVR Devices Raoul Bonan, MD5:15 p.m. Panel Discussion5:30 p.m. Adjourn for the EveningAgenda and speakers are subject to change.
  3. 3. Friday, April 26, 2013 • 7:30 a.m. – 4:15 p.m.7:30 a.m. Continental Breakfast8:00 a.m. – 10:15 a.m.Session 3: Case-Based Look at How to Avoid and Manage Complications and Difficult Patient PopulationsModerators: Wilson Y. Szeto, MD and Neal Kleiman, MD8:00 a.m. Management of Complications During Transapical AVR Vinod H. Thourani, MD8:15 a.m. Management of Vascular Complications During Transfemoral AVR Samir R. Kapadia, MD8:30 a.m. Techniques to Minimize Stroke Wilson Y. Szeto, MD8:45 a.m. Techniques in Preventing Pacemakers Jeffrey Popma, MD9:00 a.m. Management of Intraoperative Aortic Regurgitation Susheel K. Kodali, MD9:15 a.m. Management of CAD and TAVR and How to Prevent Coronary Obstruction with TAVR Susheel K. Kodali, MD9:30 a.m. When and How to Use Cardiopulmonary Bypass Wilson Y. Szeto, MD9:45 a.m. Management of the Patient with Low-EF, Low Gradient AS Howard Hermann, MD10:00 a.m. Panel Discussion10:15 a.m. Break – Please Visit Exhibits10:30 a.m. – 12:30 p.m.Session 4: TAVR Hands-On WorkshopCourse participants will be divided into two groups and will go to each station for 1 hour. • Group 1: Transcatheter Aortic Valve Replacement: CoreValve® • Group 2: Transcatheter Aortic Valve Replacement: SAPIEN Valve (TA and TF)12:30 p.m. – 1:30 p.m.Working LunchHow to Build a New Commercial Non-Academic TAVR ProgramJoshua D. Rovin, MDHow to Grow an Established Academic TAVR ProgramSamir R. Kapadia, MD1:30 p.m. Break – Please Visit ExhibitsAgenda and speakers are subject to change.
  4. 4. 2:00 p.m. – 3:45 p.m.Session 5: TAVR Outcomes and EquipoiseModerators: Susheel K. Kodali, MD and Michael J. Reardon, MD2:00 p.m. Update from the STS/ACC TVT Registry™ Michael J. Mack, MD2:15 p.m. Balloon-expandable TAVR: Worldwide Review Lars Svensson, MD2:30 p.m. Self-expandable TAVR: Worldwide Review Jeffrey Popma, MD2:45 p.m. Financial Support and Impact of a THV Program: An Administrator’s Perspective Joseph E. Bavaria, MD3:00 p.m. CMS (RUC) Coding Clarification Robert Stetson, MBA3:15 p.m. Equipoise for Intermediate Risk Trials: Rationale and Design for P2 and SURTAVI Michael J. Reardon, MD3:30 p.m. Panel Discussion4:00 p.m. Conclusions and Closing Remarks Joseph E. Bavaria, MD and E. Murat Tuzcu, MD4:15 p.m. Symposium AdjournmentAgenda and speakers are subject to change.

×